After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
Stocks Info
As a NASDAQ listed company, TARS falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Tarsus Pharmaceuticals Inc is $1.73B. A total of 0.61 million shares were traded on the day, compared to an average of 653.06K shares.
In the most recent transaction, Farrow Jeffrey S sold 13,608 shares of TARS for 40.42 per share on Jun 17 ’25. After the transaction, the insider now owns 36,704 company shares. In a previous transaction on Jun 17 ’25, Farrow Jeffrey S bought 13,608 shares at 40.42 per share.
Among the insiders who sold shares, Lin Elizabeth Yeu disposed of 1,006 shares on Jun 16 ’25 at a per-share price of $41.08. This resulted in the Chief Medical Officer holding 7,694 shares of TARS after the transaction. In another insider transaction, Lin Elizabeth Yeu bought 1,006 shares at $41.07 per share on Jun 16 ’25.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, TARS has a high of $57.28 and a low of $20.08.
As of this writing, TARS has an earnings estimate of -$0.41 per share for the current quarter. EPS was calculated based on a consensus of 1.0 estimates, with a high estimate of -$0.41 per share and a lower estimate of -$0.41.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. TARS’s latest balance sheet shows that the firm has $171.81M in Cash & Short Term Investments as of fiscal 2021. There were $1.89M in debt and $11.48M in liabilities at the time. Its Book Value Per Share was $8.15, while its Total Shareholder’s Equity was $166.73M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for TARS is Buy with a score of 4.78.
